Dynavax Technologies Corporation: Engaging with Investors
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent player in the biopharmaceutical industry, renowned for its commitment to developing and commercializing innovative vaccines. With a focus on protecting individuals from infectious diseases, Dynavax is poised to make significant strides in the healthcare sector. Recently, the company announced its plans to partake in several upcoming investor conferences, offering an opportunity for stakeholders to engage with its initiatives and achievements.
Upcoming Investor Conferences
The company is set to participate in key investor conferences, which are crucial for enhancing visibility and building relationships with potential investors. The schedule includes:
TD Cowen 45th Annual Healthcare Conference
This notable event will take place on Tuesday, March 4, providing a platform for dialogue and updates regarding their advancements in vaccine technologies.
Barclays 27th Annual Global Healthcare Conference
Shortly after, on Tuesday, March 11, Dynavax will also present at the Barclays conference. These presentations will feature essential insights into the company’s latest developments and future plans.
Webcast Access and Information
Both presentations from these conferences will be accessible via webcasts. To view these and learn more about the company’s offerings, you can visit the "Events & Presentations" page in the "Investors" section of the Dynavax website.
About Dynavax Technologies
Founded with the mission to revolutionize vaccine development, Dynavax holds a strong portfolio enriched with innovative products. The commercial-stage biopharmaceutical company has made a significant impact through its HEPLISAV-B vaccine, which is approved for use not only in the United States but also in the European Union and the United Kingdom. This vaccine addresses the prevention of hepatitis B infections for adults, showcasing the company’s dedication to public health.
Additionally, the company has developed the CpG 1018 adjuvant, integral to both HEPLISAV-B and several COVID-19 vaccines. This advancement highlights Dynavax’s ongoing commitment to tackling pressing health challenges.
Investor Relations and Contact
For media inquiries and investment information, Dynavax has dedicated personnel available:
Contact Information
Paul Cox,
Phone: 510-665-0499
Nicole Arndt,
Phone: 510-665-7264
Frequently Asked Questions
What is Dynavax Technologies Corporation known for?
Dynavax is a biopharmaceutical company focused on innovative vaccines aimed at infectious diseases.
What conferences is Dynavax participating in?
Dynavax will participate in the TD Cowen 45th Annual Healthcare Conference and the Barclays 27th Annual Global Healthcare Conference.
How can I access Dynavax's conference presentations?
Presentations can be accessed through the "Events & Presentations" page on Dynavax's website.
What products does Dynavax offer?
Dynavax’s products include HEPLISAV-B, a hepatitis B vaccine, and the CpG 1018 adjuvant used in various vaccines.
Who can I contact for investor inquiries at Dynavax?
For investor inquiries, you can contact Paul Cox or Nicole Arndt at the provided phone numbers.
